Analysis of serious adverse events. Lipid-lowering therapy revisited.
Wright
Jim M
JM
Puil
Lorri
L
Bassett
Carol Lee Ken
CL
D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D002995:Clofibric Acid / Q000009:adverse effects; D015248:Gemfibrozil / Q000009:adverse effects; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000009:adverse effects; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D009026:Mortality; D018579:Patient Selection; D012306:Risk
D000960:Hypolipidemic Agents; D002995:Clofibric Acid; D006903:Hydroxymethylglutaryl CoA Reductases; D015248:Gemfibrozil